article
Beyond templates: advancing protein–protein interaction structure prediction with AI
Dr Alan Nafiiev evaluates template-based, docking and template-free approaches to PPI prediction, highlighting how AI can enhance structural accuracy.
List view / Grid view
Artificial Intelligence
article
Inside Zasocitinib: a new model for TYK2 inhibition in immune-mediated diseases
Zasocitinib is a highly selective, investigational TYK2 inhibitor developed to target immune-mediated diseases with fewer off-target effects than traditional JAK inhibitors. This article explores its mechanism, selectivity data and clinical progress.
article
The science behind the systematic discovery of molecular glues
For decades, molecular glues have been stumbled upon rather than designed. A new scientific approach is now changing that – expanding what is considered druggable.
news
Fibroblast mapping reveals potential universal drug targets
Scientists have mapped the diversity of fibroblasts and discovered how ‘rogue’ fibroblasts drive multiple diseases, revealing drug targets that could transform treatments across the body.
news
ProRNA3D-single: new AI for drug discovery and disease research
Virginia Tech computer scientists have created a new AI tool, ProRNA3D-single, that can generate 3D models of how viral RNA binds to human proteins – a development that could speed up drug discovery.
news
Mapping lung disease: new atlas to accelerate drug discovery
Helmholtz Munich and Parse Biosciences have collaborated to create the world’s largest lung disease perturbation atlas – which could aid the discovery of new therapeutic targets and accelerate the development of future lung disease treatments.
article
Making sense of AI: bias, trust and transparency in pharma R&D
AI is increasingly used in drug discovery, but hidden bias and ‘black box’ models threaten trust and transparency. This article explores how explainable AI can turn opaque predictions into clear, accountable insights.
article
AI meets human tissue to fast-track precision medicine development
By combining human tissue models with explainable AI, researchers can analyse complex patient data to identify which treatments work best for which patients. First applied to inflammatory bowel disease, this approach could improve clinical trial success rates across many diseases.
article
Lab of the future: four technologies to watch
From precision proteomics to AI-powered immune profiling, next-generation laboratory technologies are changing how new therapies are discovered and developed. Here are four innovations set to shape the lab of the future - and the future of drug discovery.
news
AI designs new antibiotics to take on drug-resistant superbugs
Penn engineers have built an AI model that creates new antibiotics – and early tests show some work as well as existing approved drugs.
article
Animal-free drug discovery is closer with QSP
Quantitative Systems Pharmacology (QSP) is fast becoming a standard tool in drug development, offering a human-relevant way to predict drug effects before the clinic. Dr Josh Apgar of Certara explains how it is helping to cut reliance on animal testing and speed discovery.
article
Inside the search-and-develop model tackling 1,000 untreated skin diseases
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
news
New AI method maps how tuberculosis drugs destroy bacteria
Scientists at Tufts University have developed an AI tool that demonstrates how tuberculosis drugs kill bacteria – an advancement that could speed-up the discovery of shorter, more effective treatments.
article
Beyond the hype: a veteran’s honest assessment of AI in drug discovery – Part 3
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
article
Beyond the hype: a veteran’s honest assessment of AI in drug discovery – Part 2
Thibault Géoui explains why AI could finally help pharma overcome its productivity crisis and why the payoff won’t come as quickly as the optimists claim.
